Because of possible long-term toxicity, cranial radiotherapy (RT) was withheld as part of standard treatment for brain metastasis (BM) from non-seminomatous germ cell tumours (NSGCT). This study evaluates this change in management in our institute. Twenty-two consecutive patients with BM from NSGCT were analysed. Ten patients presented with BM at initial diagnosis (group 1), two patients developed BM at extra-cranial complete remission (CR) (group 2), and ten patients during treatment of the primary tumour without achieving CR (group 3). All patients received cisplatin-based induction chemotherapy. In group 1, three patients with a single metastasis and three patients with multiple BM underwent craniotomy. Five patients received chemotherapy and whole brain RT (WBRT), and five patients received chemotherapy without WBRT. In group 2, both patients underwent craniotomy for a relapse with multiple BM. One patient received additional high-dose (HD) chemotherapy with WBRT, and the other HD chemotherapy without WBRT. In group 3, one patient underwent craniotomy, seven patients received WBRT, and four patients additional HD chemotherapy. In group 1, five of ten patients (50%) achieved CR (follow-up 49–245 months), in four of those five without WBRT. In group 2, both patients achieved CR (follow-up 146 and 211 months). In group 3, one of ten patients (10%) achieved CR after HD chemotherapy and WBRT (follow-up 107 months). It is concluded that cure in patients with BM from NSGCT can be achieved with standard induction chemotherapy without WBRT.
This is a preview of subscription content, log in to check access.
Giwercman A, Carlsen E, Keiding N, Skakkebaek NE (1993) Evidence for increasing incidence of abnormalities of the human testis: a review. Environ Health Perspect 101(2):65–71. doi:10.2307/3431378PubMedCrossRefGoogle Scholar
Swerdlow AJ, Dos Santos Silva I, Reid A et al (1998) Trends in cancer incidence and mortality in Scotland: description and possible explanations. Br J Cancer 77(Suppl 3):1–54PubMedGoogle Scholar
Schmoll HJ, Souchon R, Krege S et al (2004) European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol 15:1377–1399. doi:10.1093/annonc/mdh301PubMedCrossRefGoogle Scholar
Bokemeyer C, Nowak P, Haupt A et al (1997) Treatment of brain metastases in patients with testicular cancer. J Clin Oncol 15:1449–1454PubMedGoogle Scholar
Fossa SD, Bokemeyer C, Gerl A et al (1999) Treatment outcome of patients with brain metastases from malignant germ cell tumors. Cancer 85:988–997. doi :10.1002/(SICI)1097-0142(19990215)85:4<988::AID-CNCR29>3.0.CO;2-RPubMedCrossRefGoogle Scholar
Hartmann JT, Bamberg M, Albers P et al (2003) Multidisciplinary treatment and prognosis of patients with central nervous metastases (CNS) from testicular germ cell tumor (GCT) origin. Proc Am Soc Clin Oncol 22:400Google Scholar
Rustin GJ, Newlands ES, Bagshawe KD et al (1986) Successful management of metastatic and primary germ cell tumors in the brain. Cancer 57:2108–2113. doi :10.1002/1097-0142(19860601)57:11<2108::AID-CNCR2820571103>3.0.CO;2-ZPubMedCrossRefGoogle Scholar
Rustin GJ, Newlands ES, Begent RH et al (1989) Weekly alternating etoposide, methotrexate, and actinomycin/vincristine and cyclophosphamide chemotherapy for the treatment of CNS metastases of choriocarcinoma. J Clin Oncol 7:900–903PubMedGoogle Scholar
Workman P (1986) The pharmacology of brain tumour chemotherapy. In: Bleehen NM (ed) Tumours of the brain. Springer, Berlin, pp 183–200Google Scholar